The FDA approved Biogen’s Alzheimer’s drug last year even as a panel of outside medical experts expressed concerns about its efficacy. Read More
We współpracy z: https://fortune.com/2022/12/29/congress-report-fda-approval-biogen-aduhelm-alzheimers/
SharpLink Will Stake $200M of Ethereum Through Lido’s wstETH
Sharplink plans to stake roughly 12% of its total Ethereum holdings through Lido, earning yield while staying active…
